Emergent BioSolutions (EBS) Capital Expenditures (QoQ) (2010 - 2026)
Emergent BioSolutions (EBS) Capital Expenditures (QoQ) (2010 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - |
| 10 | Emergent BioSolutions | 251.81 Mn | 110.91 Mn | 137.20 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -12.50% |
| Mar 31, 2026 | 1,300.00% |
| Dec 31, 2025 | 95.74% |
| Sep 30, 2025 | -262.07% |
| Jun 30, 2025 | -19.44% |
| Mar 31, 2025 | 111.76% |
| Dec 31, 2024 | -70.69% |
| Sep 30, 2024 | -52.07% |
| Jun 30, 2024 | 266.67% |
| Mar 31, 2024 | -92.22% |
| Dec 31, 2023 | 330.43% |
| Sep 30, 2023 | -192.93% |
| Jun 30, 2023 | 153.85% |
| Mar 31, 2023 | 109.42% |
| Dec 31, 2022 | -396.77% |
| Sep 30, 2022 | -13.08% |
| Jun 30, 2022 | -0.31% |
| Mar 31, 2022 | 61.00% |
| Dec 31, 2021 | 163.09% |
| Sep 30, 2021 | -3,862.50% |